Ghoreifi, A., Hoimes, C., Ramalingham, S., McManus, H., Kaye, D., Abern, M., & Shah, A. (2025). MP05-20 PERIOPERATIVE OUTCOMES OF CONSOLIDATIVE SURGERY FOLLOWING IMMUNOTHERAPY WITH PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN FOR ADVANCED UROTHELIAL CANCER. In Journal of Urology (Vol. 213). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1097/01.ju.0001109748.46743.aa.20

Ghoreifi, Alireza, Christopher Hoimes, Sundhar Ramalingham, Hannah McManus, Deborah Kaye, Michael Abern, and Ankeet Shah. “MP05-20 PERIOPERATIVE OUTCOMES OF CONSOLIDATIVE SURGERY FOLLOWING IMMUNOTHERAPY WITH PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN FOR ADVANCED UROTHELIAL CANCER.” In Journal of Urology, Vol. 213. Ovid Technologies (Wolters Kluwer Health), 2025. https://doi.org/10.1097/01.ju.0001109748.46743.aa.20.

Ghoreifi A, Hoimes C, Ramalingham S, McManus H, Kaye D, Abern M, et al. MP05-20 PERIOPERATIVE OUTCOMES OF CONSOLIDATIVE SURGERY FOLLOWING IMMUNOTHERAPY WITH PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN FOR ADVANCED UROTHELIAL CANCER. In: Journal of Urology. Ovid Technologies (Wolters Kluwer Health); 2025.

Ghoreifi, Alireza, et al. “MP05-20 PERIOPERATIVE OUTCOMES OF CONSOLIDATIVE SURGERY FOLLOWING IMMUNOTHERAPY WITH PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN FOR ADVANCED UROTHELIAL CANCER.” Journal of Urology, vol. 213, no. 5S, Ovid Technologies (Wolters Kluwer Health), 2025. Crossref, doi:10.1097/01.ju.0001109748.46743.aa.20.

Ghoreifi A, Hoimes C, Ramalingham S, McManus H, Kaye D, Abern M, Shah A. MP05-20 PERIOPERATIVE OUTCOMES OF CONSOLIDATIVE SURGERY FOLLOWING IMMUNOTHERAPY WITH PEMBROLIZUMAB PLUS ENFORTUMAB VEDOTIN FOR ADVANCED UROTHELIAL CANCER. Journal of Urology. Ovid Technologies (Wolters Kluwer Health); 2025.